# OnCo record tallac-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/tallac-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "tallac-therapeutics" ;
  schema:name "Tallac Therapeutics"@en ;
  schema:description "Tallac Therapeutics builds antibodies that carry an immune-activating molecule into tumours, so the body's own defences attack the cancer. Its lead medicine is in early human trials and has a fast-track review status in bile duct cancer."@en ;
  schema:url <https://onco.cc/companies/tallac-therapeutics/>, <https://www.tallactherapeutics.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.tallactherapeutics.com/>, <https://www.tallactherapeutics.com/news/tallac-therapeutics-launches-with-62-million-in-series-a-financing-to-advance-novel-immunotherapies-for-cancer/>, <https://www.tallactherapeutics.com/news/fda-grants-fast-track-designation-to-tac-001/> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/immune-stimulating-adc/>, <https://onco.cc/technologies/adc/> .